In device-detected AF, DOACs vs. aspirin or placebo reduce ischemic stroke and increase major bleeding

Area of Science:

• Cardiology
• Neurology
• Clinical Trials

Background:

• Atrial fibrillation is a common arrhythmia associated with increased stroke risk.
• Device-detected atrial fibrillation (DDAF) presents unique challenges in stroke prevention management.
• Current guidelines offer limited recommendations for anticoagulation in DDAF.

Purpose of the Study:

• To evaluate the efficacy of direct oral anticoagulants (DOACs) for stroke prevention in patients with DDAF.
• To conduct a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials.
• To inform clinical decision-making regarding anticoagulation in the DDAF population.

Main Methods:

• Study-level meta-analysis combining individual patient data from the NOAH-AFNET 6 and ARTESiA trials.
• Inclusion of patients diagnosed with DDAF.
• Assessment of stroke and systemic embolism as primary outcomes.

Main Results:

• DOACs did not significantly reduce the risk of stroke or systemic embolism compared to placebo in patients with DDAF.
• No significant reduction in the composite outcome of stroke, systemic embolism, or death from cardiovascular causes was observed with DOACs.
• Bleeding events were more frequent in the DOAC groups, consistent with known safety profiles.

Conclusions:

• DOACs are not effective for preventing stroke in patients with DDAF.
• The findings challenge the routine use of DOACs in this specific patient population.
• Further research is needed to identify optimal strategies for stroke risk management in DDAF.